United States: Aiming To Foster Innovation, FDA Proposes Regulatory Framework Specific To Prescription Drug Software

On November 20, 2018, the U.S. Food and Drug Administration ("FDA") issued a Federal Register notice seeking public comment on FDA's proposed framework for regulating prescription drug-use-related software ("PDURS"), the agency's latest move in modernizing the regulatory requirements for digital health technologies (see prior Ropes & Gray alerts summarizing FDA's Digital Health Innovation Action Plan and new Software Precertification Program and discussing two digital health software draft guidances). Under the proposed framework, which FDA intends to develop into a draft and, ultimately, a final guidance document, FDA would regulate the output of PDURS—software "disseminated by or on behalf of a drug sponsor that accompanies one or more of the sponsor's prescription drugs (including biological drug products)"—as drug labeling. As such, the software output would be subject to FDA's regulations for FDA required labeling or promotional labeling, as applicable.

The proposed framework is intended to align with FDA's ongoing digital health initiatives and foster innovation while also ensuring that drug sponsors' communications (in the form of software outputs) are consistent with applicable labeling requirements. In public remarks announcing the proposed framework, Commissioner Gottlieb expressed his view that the "flexible concepts" described in the proposed framework will encourage more drug sponsors to advance beneficial and innovative software apps with their products. He added that FDA "is committed to considering and weighing all comments as we develop draft guidance."

The Proposed Framework

Relevance of Existing Digital Health Device Policies. The proposed framework does not address whether particular software constitutes a medical device and would not affect FDA's existing policies in this area, such as FDA's guidance documents relating to mobile medical applications and clinical and patient decision support software. FDA anticipates that some PDURS will meet the definition of a device, while other PDURS will not. Separate and apart from whether PDURS is considered a device, the proposed framework would regulate the output of such software as drug labeling (i.e., the software may be regulated as a device in addition to its output being regulated as drug labeling).

Scope and Applicability. The proposed framework would only apply to software disseminated by or on behalf of a drug sponsor and explicitly would not apply to "third party software developers who independently develop or disseminate software for use with prescription drugs." However, if a drug sponsor licenses software originally developed by a third party and then disseminates the software for use in conjunction with the sponsor's drug, such software would be subject to the proposed framework. Additionally, software that is branded with the name of a drug product is considered to be disseminated by or on behalf of the sponsor, even if the software is otherwise available or is not solely related to the specific product's use, such as an app that provides medication reminders, symptom tracking, or general information about the disease. The "output" of PDURS is described as the material presented to the end user and includes screen displays, alerts, reminders, audio messages, vibrations, or sounds. FDA asserts that such outputs constitute drug labeling because they "accompan[y] a drug, for example by explaining how to use the drug . . . or by supplementing the use of the drug." This assertion is based upon FDA's historically broad view of "labeling" under the Federal Food, Drug, and Cosmetic Act and its expansive interpretation of Kordel v. United States, 355 U.S. 345, 350 (1948), the seminal Supreme Court case addressing the proper scope of "labeling."

When PDURS Information May Be Included in FDA-Required Labeling. FDA generally classifies drug labeling as either (a) FDA-required labeling (e.g., prescribing information, medication guide), which contains information essential to the provider's decision to prescribe the drug or the patient's safe and effective use of the drug, or (b) promotional labeling, which encompasses any other labeling devised for product promotion. FDA anticipates that most forms of PDURS output would be considered promotional labeling and not subject to prior FDA approval. Nevertheless, the proposed framework contemplates two scenarios in which PDURS information may be included in the FDA-required drug labeling and therefore subject to prior FDA approval:

  1. when use of the PDURS with the drug results in a clinically meaningful improvement compared to use of the drug alone, as demonstrated through substantial evidence, and the sponsor submits such evidence as part of an application (e.g., software that improves patient compliance and improves outcomes of the relevant clinical endpoint compared to drug use alone), or
  2. where the PDURS provides a function or information that is essential to one or more intended uses of a drug-led drug-device combination product (e.g. software that displays tracking information for a drug product with an ingestible event marker).

Software output information included in the approved product label would be subject to heightened controls under the FDA-required drug labeling regulations. Although FDA does not squarely address this issue, any post-approval changes to the PDURS output in these scenarios, such as changes in displays or sounds, could potentially require changes to the approved labeling and therefore trigger the need for FDA approval of a supplemental new drug application or the submission of a CBE-30 supplement prior to implementing the changes.

PDURS Output As Promotional Labeling and Associated Obligations. FDA proposes that if PDURS output information is not included in FDA-required labeling as described above, then the PDURS output would be considered promotional labeling subject to FDA's postmarket reporting regulations under 21 C.F.R. § 314.81(b)(3)(i) and 601.12(f). Specifically, sponsors would be required to submit such output to FDA at the time of initial dissemination using Form 2253, the same form sponsors currently use to submit other promotional materials. Such submissions would include, among other things, screenshots or other appropriate representations of the user experience for the PDURS. Additionally, FDA proposes that sponsors would be required to submit updates whenever a software update results in changes to the user experience. FDA does not specify how significant a change must be to trigger a new submission requirement.

FDA also explains that, like other promotional labeling, PDURS output should be consistent with the FDA-required labeling based on the factors described in FDA's recent guidance document on this topic (see prior Ropes & Gray alert). FDA anticipates that most uses of PDURS output would not pose an increased risk compared to other promotional labeling currently in use. FDA asserts, however, that certain software output may provide recommendations that could "direct patients to make decisions about their drug or disease that would normally be made in consultation with a healthcare provider," such as software output that provides recommendations on when to contact their healthcare provider or how to adjust their dose based on their symptoms and other related information. For these software outputs, FDA recommends the sponsor submit the software output through FDA's voluntary, pre dissemination advisory comment process so that the sponsor can obtain feedback from FDA on whether the output is consistent with the FDA-required labeling. PDURS that has received clearance or approval as a medical device does not need to be submitted through the advisory comment process; however, the sponsor is still required to comply with the 2253 submission requirements for the PDURS output at the time of dissemination.

Points for Consideration and Practical Implications

FDA is soliciting comments regarding the proposed framework on a variety of specific issues, including, among others:

  • Whether the proposed approach adequately fosters innovation;
  • Recommendations for how to appropriately address the balancing of benefit information and risk information when PDURS output includes a benefit claim about the drug;
  • The appropriate types of software output for which the pre-dissemination, voluntary advisory comment process is recommended;
  • Actions to ensure end users have access to PDURS appropriate to the specific drug dispensed (e.g., in cases of generic substitution); and
  • Issues to consider to facilitate timely generic competition for prescription drugs that are approved with PDURS output included in the FDA-required labeling.

If implemented, the proposed framework could have a significant impact on both drug product sponsors looking to innovate with the use of digital health software and the developers of such software. Of particular importance, the requirement to submit PDURS output on Form 2253 may come as a surprise to some sponsors who previously did not consider such software to be labeling. More generally, pharmaceutical companies likely would need to exert heightened control over any software applications that are branded with the company's drug product name because such applications would be considered PDURS if disseminated by or on behalf of the company. Companies likely would also need to become more involved in the process for software updates, as any update to the user experience could trigger the need for a Form 2253 or CBE-30 submission to FDA or potentially even prior FDA approval (if the update is a major change affecting PDURS output information included in the FDA-required labeling). Furthermore, given ambiguity in the proposed framework regarding when software disseminated by or on behalf of the sponsor "accompanies" a prescription drug, companies would need to consider whether the framework would apply to third-party software in which the company has purchased ad space or has otherwise paid for the inclusion of branded product communications.

Other questions raised by FDA could have broader implications that should be carefully considered. For example, determining the appropriate balancing of benefit and risk information in PDURS output could impact the balancing of information in other digital media communications. Additionally, the expanded use of PDURS by branded drug sponsors could raise complex issues related to generic competition.

FDA will be accepting comments until January 22, 2019. Ropes & Gray will continue to monitor these and other developments in the digital health space.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions